Teva Pharmaceutical Industries
在场
是其中之一......
Teva Pharmaceutical Industries 是一家在股票代码 TEVA (IL) 下上市的公司。
Teva Pharmaceutical Industries 在 20 个国家有直接业务。Teva Pharmaceutical Industries 拥有 21家子公司，其中包括 Medis Germany、Pliva 和 Teva ANZ。
高管
查看带有其 118 名主要高管的组织结构图
Teva Pharmaceutical Industries 搜索最多的简介
- Richard Francis, Director, President and Chief Executive Officer
- Sol Barer, Chairman of the Board
- Tal Zaks, Director
高管在Teva Pharmaceutical Industries变化
- Placid Jover已作为Executive Vice President and Chief Human Resources Officer加入公司 (新闻发布的2024八月28号).
- Matthew ShieldsMatthew Shields 将于20246月3作为 Executive Vice President of Global Operations 加入公司 (新闻发布的2024五月16号).
- Eric Drapé, Executive Vice President, Global Operations, 将于 20246月3 退休 (新闻发布的2024五月16号).
创建提醒
跟踪 Teva Pharmaceutical Industries 的高管变动
药店
Teva Pharmaceutical Industries 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Teva Pharmaceutical Industries 的最新新闻稿
- Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
- Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
- Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
- Teva to Present at the Jefferies London Healthcare Conference
- Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
- Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
- Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
- Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
- New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
- View more press releases Close
通过电子邮件
